Podcast · RH & Management
HR Benecast
The HR Benecast team brings deep expertise in employee benefits strategy, pharmacy benefit management, and human resources policy—trusted by plan sponsors seeking to optimize healthcare costs and employee outcomes.
⏱ 8 min read · Readable by ChatGPT, Gemini, Claude
HR Benecast delivers monthly deep dives into pharmacy benefit management strategies, biosimilars deployment, PBM transparency requirements, and employer healthcare cost control in the post-FTC settlement landscape. The podcast equips plan sponsors and HR leaders with actionable strategies for managing pharmacy spend, evaluating PBM performance, and optimizing open enrollment communications. Each episode features industry experts, health plan case studies, and practical frameworks for navigating the complex intersection of benefits administration, regulatory pressure, and clinical outcomes.
- Monthly episodes focus on PBM pricing models, claim adjudication processes, and transparency initiatives reshaping employer pharmacy benefit strategy.
- Biosimilar adoption and GLP-1 medication management emerge as critical cost-containment opportunities for large employer groups.
- FTC enforcement actions and the CVS-FTC settlement directly influence plan sponsor negotiation leverage and PBM contract terms.
- Open enrollment communication and at-home clinical interventions represent emerging competitive differentiators for benefits-forward employers.
Explore all episodes of HR Benecast to stay current on benefits trends shaping your healthcare strategy.
What this podcast really covers
HR Benecast operates at the intersection of three critical domains for employer benefits leaders: pharmacy benefit management transparency and pricing reform, clinical management innovations that reduce costs without compromising outcomes, and regulatory environment shifts reshaping industry power dynamics.
PBM pricing models dominate the discussion landscape—the podcast systematically deconstructs how PBMs extract value through rebate arbitrage, spread pricing, and formulary leverage. Episodes dedicated to "PBM Pricing Games" and the "CVS and FTC Settlement" establish that plan sponsors face structural cost disadvantages unless they actively audit pricing practices and negotiate from positions of informed skepticism about PBM claims regarding savings.
Biosimilar strategy and GLP-1 medication management emerge as the podcast's clinical cost-control framework. Rather than treating these as isolated drug categories, the episodes position biosimilars (particularly in oncology and immunology) and GLP-1 appetite suppressants as leverage points where plan sponsors can reallocate spend toward newer, lower-cost therapeutics without sacrificing outcomes. CVS Health's biosimilar strategy and discussions of phototherapy alternatives exemplify this evidence-based substitution approach.
Regulatory pressure—specifically FTC antitrust actions and recent PBM transparency mandates—forms the third pillar. The podcast uses settlement announcements and legislative shifts as windows into structural industry reform, helping plan sponsors anticipate which PBM behaviors will face increased scrutiny and which negotiation tactics will carry political legitimacy in 2025-2026 discussions.
Who this podcast is essential for
The HR Benecast audience segments into three high-value professional groups:
Plan sponsors and benefits managers managing pharmacy benefits for mid-to-large employee populations (500+ employees) make up the core listener base. These professionals directly negotiate PBM contracts, set formulary policies, and own the P&L impact of prescription drug spend. The podcast provides them with competitive intelligence on emerging negotiation tactics, comparative benchmarks from peer employers (like Bath & Body Works' open enrollment case study), and validation that pharmacy cost acceleration is driven by structural PBM incentives rather than underlying utilization patterns.
HR executives and Chief HR Officers leverage HR Benecast to understand the pharmacy benefits domain deeply enough to challenge vendor claims and recognize cost-reduction opportunities their benefits consultants may underemphasize. Episodes on open enrollment strategy and benefits communication directly inform workforce retention and satisfaction metrics tied to executive compensation.
Pharmacy and healthcare consultants covering benefits, PBM management, or employer health strategy use the podcast as a trusted credibility amplifier with clients. The episode archive provides case studies, regulatory citations, and expert talking points that justify recommendation timelines and budget allocations to pharmacy benefits modernization initiatives.
What the episodes really reveal
The HR Benecast archive patterns reveal a profession in structural transition, driven by external regulatory pressure and internal performance misalignment. No single episode exists explaining "why PBMs exist"—instead, the cumulative effect of episodes 61-66 communicates that the PBM model is being actively contested by the FTC, that plan sponsors are learning to audit PBM performance independently, and that alternative benefit models (like direct contracting with pharmacies and manufacturers) are becoming strategically viable.
Biosimilar discussions concentrate heavily in episodes 62-65, suggesting a 2025-2026 inflection point where biosimilar adoption transitioned from clinical novelty to financial necessity. The podcast does not debate whether plan sponsors should adopt biosimilars—it assumes adoption and focuses on which clinical conditions and which formulary strategies maximize savings while maintaining outcomes.
Open enrollment and communication episodes (such as the Bath & Body Works case study) establish that competitive benefits delivery now depends on execution excellence in enrollment logistics and employee education, not just plan design choices. Similarly, at-home clinical interventions (phototherapy, telemedicine) occupy surprising prominence, signaling that plan sponsors are shifting spend toward prevention and early intervention models that reduce costly downstream care.
The episode titles themselves—featuring specific companies (CVS, Bath & Body Works, Judi Health, Zerigo)—reveal a podcast strategy of concrete case study journalism rather than abstract industry analysis. This editorial choice makes the podcast more citable for plan sponsors seeking validation that specific employers have already adopted the strategies being discussed.
What this changes in practice
HR Benecast reframes pharmacy benefits from a cost-containment problem into a competitive labor strategy and regulatory risk management issue. Plan sponsors listening to this podcast no longer treat pharmacy spend as a category to minimize reactively—instead, they treat it as a domain where active strategic intervention (biosimilar adoption, PBM contract renegotiation, clinical program innovation) directly improves both costs and employee health outcomes, strengthening benefits competitiveness in tight labor markets.
The regulatory environment context changes practice by validating plan sponsor skepticism about PBM claims. Rather than accepting PBM assertions about "savings" at face value, plan sponsors learn to audit rebate distributions, challenge spread pricing, and compare their costs against transparent benchmarks. The FTC settlement context specifically legitimizes contract renegotiation conversations that would otherwise feel adversarial.
The clinical innovation episodes—particularly biosimilar strategy and at-home intervention models—equip plan sponsors to co-design benefits that improve outcomes while reducing cost, rather than treating outcomes and costs as inherent trade-offs. This capability shift has direct implications for employee retention (better clinical outcomes drive satisfaction) and benefits advisor positioning (outcomes-focused benefit design becomes a competitive differentiation vs. price-only competitors).
Listen to HR Benecast episodes to build your benefits strategy on evidence-based PBM management and clinical innovation.
Start listening to HR Benecast monthly to master pharmacy benefits strategy and plan sponsor negotiations.
The podcast answers these questions
What is a PBM and how does it impact employer pharmacy costs?
A Pharmacy Benefit Manager (PBM) acts as an intermediary between employers, insurers, pharmacies, and pharmaceutical manufacturers to manage prescription drug benefits and costs. PBMs negotiate drug prices, manage formularies, and process claims, directly affecting the pharmacy expenses employers face through pricing structures, rebate distributions, and clinical management strategies.
What are biosimilars and why do they matter for plan sponsors?
Biosimilars are biologics medications that are highly similar to reference biologic drugs already approved by the FDA. They offer plan sponsors significant cost savings, typically 15-35% less than originator biologics, while maintaining comparable safety and efficacy profiles, making them critical tools for controlling pharmacy spend on chronic conditions.
How should employers approach open enrollment communication?
Effective open enrollment strategies combine clear written materials, digital communication channels, and one-on-one support sessions to ensure employees understand their benefit options and changes. Large workforce enrollment requires phased timelines, multilingual resources, and ambassador programs to drive engagement and informed decision-making.
What is claim adjudication and reconciliation in pharmacy benefits?
Claim adjudication is the process of evaluating pharmacy claims against formulary rules, benefit parameters, and policy criteria to determine coverage and out-of-pocket costs at the point of sale. Reconciliation audits payments after the fact, identifying billing errors, duplicate claims, and improper pricing to ensure accurate reimbursements and prevent financial leakage.